Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

被引：4
|
作者：
William, Basem M. [1 ]
Huang, Ying [1 ]
Johnson, Amy [2 ]
Brammer, Jonathan E. [3 ]
Reneau, John C. [2 ]
Maakaron, Joseph [2 ]
Larbi, Ruth [2 ]
Grantier, Cara [2 ]
Hoffman, Corinne [2 ]
Ayyappan, Sabarish [3 ]
Baiocchi, Robert A. [2 ]
Epperla, Narendranath [2 ]
Christian, Beth A. [1 ]
Alinari, Lapo [2 ]
Maddocks, Kami J. [2 ]
Chung, Catherine [2 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp & Richard J Solove Res I, Div Hematol, Columbus, OH 43210 USA
[3] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-123801
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2853
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis
    Brammer, Jonathan E.
    Zinzani, Pier Luigi
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Jacobsen, Eric D.
    Gritti, Giuseppe
    Litwak, Debra
    Cohan, David
    Katz, Danica J.
    Mehta-Shah, Neha
    Pro, Barbara
    Horwitz, Steven M.
    BLOOD, 2021, 138
  • [42] A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas
    Mehta-Shah, Neha
    Moskowitz, Alison J.
    Lunning, Matthew
    Lynch, Peggy
    Scheuerman, Mark
    Kumar, Anita
    Gerecitano, John F.
    Zelenetz, Andrew D.
    Hamlin, Paul A., Jr.
    Noy, Ariela
    Matasar, Matthew J.
    Palomba, M. Lia
    Younes, Anas
    Schaffer, Wendy
    Grewal, Ravinder
    Rademaker, Jurgen
    Sauter, Craig S.
    Dahi, Parastoo B.
    Myskowski, Patricia
    Kheterpal, Meenal
    Dogan, Ahmet
    Pulitzer, Melissa
    Tang, Laura
    Ni, Ai
    Horwitz, Steven M.
    BLOOD, 2016, 128 (22)
  • [43] A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy
    Wang, M.
    Fayad, L.
    Hagemeister, F.
    Neelapu, S.
    Bell, N.
    Byrne, C.
    Knight, R.
    Zeldis, J.
    Kwak, L.
    Romaguera, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
    Zinzani, Pier Luigi
    Musuraca, Gerardo
    Tani, Monica
    Stefoni, Vittorio
    Marchi, Enrica
    Fina, Mariapaola
    Pellegrini, Cinzia
    Alinari, Lapo
    Derenzini, Enrico
    de Vivo, Antonio
    Sabattini, Elena
    Pileri, Stefano
    Baccarani, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) : 4293 - 4297
  • [45] Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
    Querfeld, Christiane
    Kuzel, Timothy M.
    Kim, Youn H.
    Porcu, Pierluigi
    Duvic, Madeleine
    Musiek, Amy
    Rook, Alain H.
    Mark, Lawrence A.
    Pinter-Brown, Lauren
    Hamid, Oday
    Lin, Boris
    Bian, Ying
    Boye, Mark
    Day, Jeannette M.
    Rosen, Steven T.
    LEUKEMIA & LYMPHOMA, 2011, 52 (08) : 1474 - 1480
  • [46] A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)
    Park, Byeong-Bae
    Kim, Won Seog
    Suh, Cheolwon
    Hong, Jung Yong
    Yang, Deok-Hwan
    Lee, Won Sik
    Do, Young Rok
    Koh, Young Il
    Won, Jong-Ho
    Kim, Min Kyoung
    Jo, Jae-Cheol
    Hyun, Shin Young
    Kim, Jeong-A
    Oh, Young Ha
    Lee, Seung-Sook
    LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3251 - 3257
  • [47] Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).
    Duvic, Madeleine
    Becker, Juergen C.
    Dalle, Stephane
    Vanaclocha, Francisco
    Bernengo, Maria Grazia
    Lebbe, Celeste
    Dummer, Reinhard
    Hirawat, Samit
    Zhang, Lei
    Marshood, Miriam
    Laird, Glen
    Prince, H. Miles
    BLOOD, 2008, 112 (11) : 370 - 370
  • [48] Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis
    Sano, Dahlia
    Liu, Nicholas
    Knowles, Scott
    MacEwan, Joanna P.
    Wang, Shu
    Wogen, Jenifer
    Yu, Kristina S.
    Lee, Seung Tae
    CURRENT ONCOLOGY, 2024, 31 (05) : 2598 - 2609
  • [49] A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)
    Chavez, Julio C.
    Foss, Francine M.
    William, Basem M.
    Brammer, Jonathan E.
    Smith, Sonali M.
    Prica, Anca
    Zain, Jasmine M.
    Tuscano, Joseph M.
    Glenn, Martha
    Mehta-Shah, Neha
    Wang, Ben X.
    Zantinge, Stephanie
    Wang, Lisa
    Zhang, Ling
    Boutrin, Anmarie
    Zhao, Weiguang
    Cheng, Lily
    Standifer, Nathan
    Carlesso, Gianluca
    Moscow, Jeffrey
    Siu, Lillian
    BLOOD, 2020, 136
  • [50] PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
    O'Connor, O.
    Pro, B.
    Pinter-Brown, L.
    Popplewell, L.
    Bartlett, N.
    Lechowicz, M.
    Savage, K.
    Coiffier, B.
    Saunders, M.
    Horwitz, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345